{"url_path":"/sec/rlay/8-k/2026-04-27/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-04-27","source_url":"https://www.sec.gov/Archives/edgar/data/1812364/0001193125-26-179404-index.html","accession_number":"0001193125-26-179404","cik":"0001812364","ticker":"RLAY","issuer_name":"Relay Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1812364/0001193125-26-179404-index.html","primary_entity_key":"0001812364","primary_entity_name":"Relay Therapeutics, Inc."},"word_count":86,"has_tables":true,"body_markdown":"## Item 9.01 Financial Statements and Exhibits.\n\n99.1\n\n[Press release issued by Relay Therapeutics, Inc. on April 27, 2026, furnished herewith.](rlay-ex99_1.htm)\n\n99.2\n\n[Corporate presentation, dated April 27, 2026, furnished herewith.](rlay-ex99_2.htm)\n\n104\n\nCover Page Interactive Data File (embedded within Inline XBRL document)\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\nRELAY THERAPEUTICS, INC.\n\n \n\n \n\n \n\n \n\nDate:\n\nApril 27, 2026\n\nBy:\n\n/s/ Soo-Yeun Lim\n\n \n\n \n\n \n\nSoo-Yeun Lim\nGeneral Counsel"}